C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.

[1]  P. Ridker,et al.  Blood Pressure and Inflammation in Apparently Healthy Men , 2001, Hypertension.

[2]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[3]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[4]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[5]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[6]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[7]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[8]  N Rifai,et al.  Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. , 2001, Clinical chemistry.

[9]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[10]  P. Ridker,et al.  Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. , 2001, Clinical chemistry.

[11]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[12]  N Rifai,et al.  High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. , 2000, Clinical biochemistry.

[13]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[14]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[15]  D. Strachan,et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. , 2000, European heart journal.

[16]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[17]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[18]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[19]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[20]  C. Heeschen,et al.  Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. , 2000, Journal of the American College of Cardiology.

[21]  N. Rifai,et al.  Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. , 2000, Clinical chemistry.

[22]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[23]  D. Strachan,et al.  C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. , 2000, Atherosclerosis.

[24]  E. Ford,et al.  Prevalence of nonfatal coronary heart disease among American adults. , 2000, American heart journal.

[25]  M. Leinonen,et al.  Infections, inflammation, and the risk of coronary heart disease. , 2000, Circulation.

[26]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[27]  C. Stehouwer,et al.  Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Libardoni,et al.  C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction. , 1999, Cardiologia.

[29]  A. Rebuzzi,et al.  Enhanced inflammatory response in patients with preinfarction unstable angina. , 1999, Journal of the American College of Cardiology.

[30]  C. Boissonnet,et al.  Independent prognostic value of elevated C-reactive protein in unstable angina. , 1999, Circulation.

[31]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[32]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[33]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[34]  A. Hofman,et al.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[36]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[37]  N. Fiotti,et al.  Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. , 1999, Atherosclerosis.

[38]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[39]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Lijmer,et al.  Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. , 1999, Cardiovascular research.

[41]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[42]  A. Rebuzzi,et al.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.

[43]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[44]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[45]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[46]  E. Vicaut,et al.  Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. , 1998, The American journal of cardiology.

[47]  A. Rebuzzi,et al.  Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. , 1998, The American journal of cardiology.

[48]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[49]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[50]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[51]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[52]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[53]  R. Tracy.  Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.

[54]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[55]  P. Libby,et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.

[56]  P. Ridker,et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.

[57]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[58]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[59]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[60]  Euroaspire Investigators.  148 EUROASPIRE: A European Society of Cardiology survey for the potential for secondary prevention of coronary heart disease in nine European countries , 1997 .

[61]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[62]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[63]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[64]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[65]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[66]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[67]  Y. Tsujita,et al.  Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[68]  W. Kannel.  Range of serum cholesterol values in the population developing coronary artery disease. , 1995, The American journal of cardiology.

[69]  J. Mair,et al.  Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. , 1995, Clinical chemistry.

[70]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[71]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[72]  G. Assmann,et al.  Association of Variables of Coagulation, Fibrinolysis and Acute-phase with Atherosclerosis in Coronary and Peripheral Arteries and those Arteries Supplying the Brain , 1995, Thrombosis and Haemostasis.

[73]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[74]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[75]  W. Weintraub,et al.  Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.

[76]  K. Pietilä,et al.  Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. , 1987, British heart journal.

[77]  I. Das,et al.  Raised C-reactive protein levels in serum from smokers. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[78]  P. Dodson,et al.  RETINAL VEIN OCCLUSION: C‐REACTIVE PROTEIN AND ARTERIAL HYPERTENSION , 1984, Acta ophthalmologica.

[79]  J. Volanakis.  COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.

[80]  A. Maseri,et al.  Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. , 1982, British heart journal.

[81]  D. Karp,et al.  Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. , 1978, The Journal of clinical investigation.

[82]  R. Tracy,et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[83]  M. Margaglione,et al.  C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[84]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[85]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .